The hosts trade their own experiences with retatrutide, the weight loss drug still in trials, and debate whether it's worth it. Personal accounts, not medical advice.
Recap by typeshit. Full story at Tristan Huseby.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
A piece on questions about tirzepatide and breast cancer risk. Only the headline is available, so check the source for what the evidence says.
Jay Goldberg of the Consumer Choice Center argues the $50 copay only covers some Medicare patients, and points to PBM reform and competition instead.
Lilly is appealing a court loss over whether retatrutide counts as a biologic. A win could mean 12 years of exclusivity instead of 5 and a later Medicare price fight.
Loading…